Replies to post #6687 on Synaptogenix Inc (SNPX)

[Battle Ready]

I'm not expecting Neurotrope to remain a fully independent entity through the retail sale of Bryostatin...

I'm very impressed with the current management team and there appears to be a strategy and methodology to everything they are doing.

Fragile X being what it is, will very likely have a well heeled partner (children's hospital or foundation) to fund the trial once the details have been worked out. This could be the next meaningful announcement in terms of the stock price getting a bump. Not knowing anything about what this will ultimately look like, I'm thinking this should be worth several dollars to the share price...

To my thinking, a successful confirmation trial will do two things: 1) provide a potential fast track with the FDA, and then correspondingly, 2) create a more tangible higher valuation basis for a sale or dilutive partnership with a big pharma company. We are talking about the potential of a priceless asset, there should be a significant bidding war in the event that the confirmation trial goes as expected/hoped for...

I would bet that they could sell the company right now for quite a bit more than the current market valuation. Hypothetically, if they were offered $300 million, I'm confident they would turn it down without a second thought based upon the expectation of where the confirmation trial is going and what they can get after that...